The Lancet

Safety, tolerability, pharmacokinetics, and pharmacodynamics of the first-in-class GLP-1 and amylin receptor agonist, amycretin: a first-in-human, phase 1, double-blind ...

aResearch and Early Development, Novo Nordisk A/S, Måløv, Denmark bDevelopment, Novo Nordisk A/S, Søborg, Denmark ...